What Лидаза Treats: Main Uses and Benefits

Core Therapeutic Support

The medication is applied across domains where additional symptomatic support is needed in specific clinical scenarios. It is utilized to assist with various symptom-driven clinical presentations where tissue permeability is a factor.

This enzyme plays a role in managing symptoms related to local anesthetic spread and may assist with rapid, widespread distribution, which is relevant in contexts marked by increased discomfort or tension. This supports patients who require fluid management by assisting with the comfortable absorption of necessary subcutaneous fluids, a helpful consideration in patient groups like small children and older adults where alternate methods are not easily available.

Symptom Management and Functional Benefit

The medication is commonly used across conditions presenting with localized discomfort, including situations requiring subcutaneous fluid administration, as an aid in subcutaneous urography, and may be part of symptomatic management to support the spread of co-administered injected drugs. The medication is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms of localized post-injection injury become temporarily overwhelming, such as with accidental drug leakage (extravasation) or the need to manage certain dermal filler materials in acute situations. Furthermore, it is relevant for easing challenging symptoms associated with excessive fibrous tissue, such as mature scars or localized sclerotic conditions. The primary benefit sought often contributes to improved tissue flexibility and assists with the effective and comfortable delivery of localized treatments.

---

Quick Fact: Relief for Tissue Tension and Discomfort The medication is commonly used to help manage symptom clusters associated with tissue hardness, localized swelling, and restricted movement, providing support that helps ease the overall symptom burden during symptomatic periods.

Official Population Eligibility and Restrictions

The regulatory information for Лидаза (Hyaluronidase) strictly defines the populations permitted to use the medicine and those who are excluded. The most crucial non-eligibility rule is the absolute contraindication for any patient with a known hypersensitivity or allergy to hyaluronidase or any excipient in the formulation.

Use is also strictly prohibited at certain local sites. The medicine must not be injected into or around an infected or acutely inflamed area due to the potential risk of spreading the condition. It is also prohibited from being used to treat bites or stings and must not be applied directly to the cornea.

Eligibility for the geriatric population is generally unrestricted. In contrast, use in pediatric patients is highly regulated: specific maximum volume and rate limits must be followed for infants, premature infants, and children under three years old. For pregnant women, administration is conditional, permitted only if clearly needed, and caution is advised for nursing mothers as excretion into human milk is unknown.

Interactions with other medicines and products

The interaction profile for Лидаза (Hyaluronidase) is defined by its function as a tissue permeability modifier, leading primarily to local pharmacodynamic interactions rather than systemic metabolic effects. Official regulatory documents outline two core interaction types: enhancement of absorption and mandatory administration restrictions.

Pharmacodynamic Interaction Patterns

Co-administration with the enzyme results in a pharmacodynamic enhancement of local dispersion, which leads to increased systemic absorption and exposure of other medicinal products. This effect is specifically documented for substances intended for subcutaneous or intramuscular administration, including Local Anesthetics and Radiographic Contrast Media. The increased systemic exposure (AUC/Cmax) of the co-administered drug is a formally noted outcome.

Substances whose effects may be affected by this interaction include Furosemide and Phenytoin. Furthermore, the enzyme's function itself can be inhibited by co-administered high doses of Salicylates, certain Corticosteroids, and Oestrogens.

Administration Restrictions and Incompatibilities

Official labeling specifies mandatory administration restrictions due to physical and chemical incompatibility with certain substances. Лидаза must not be mixed in the same syringe or solution with Furosemide, Phenytoin, or High-Dose Benzodiazepines. This is a requirement for separation of administration to avoid altering the integrity of the solutions. No specific interactions with food, alcohol, or herbal products are documented in regulatory sources.

Enzymatic Degradation of Hyaluronan (Hyaluronic Acid)

Лидаза acts through the enzyme hyaluronidase, which constitutes its active substance. This mechanism engages the extracellular matrix (ECM) as its primary site of action. Hyaluronidase directly targets the glycosaminoglycan hyaluronic acid (HA), a large polymer that contributes significantly to the viscosity and structure of connective tissue. The enzyme initiates a mechanistic cascade by cleaving the beta-1,4-glycosidic bonds within the HA polymer chain. This interaction results in the depolymerization of HA into smaller, lower-molecular-weight fragments.

---

Extracellular Matrix Remodeling and Tissue Permeability

The depolymerization of HA by hyaluronidase reduces the viscosity and alters the physicochemical properties of the ECM. This modification influences the localized fluid dynamics and molecular movement within the tissues. The resulting system-level physiological consequence is a temporary and reversible increase in tissue permeability, which facilitates the diffusion and spread of co-administered molecules or fluids across the connective tissue barrier.

How Лидаза Is Used: Official Administration Guidelines

The administration of Лидаза (Hyaluronidase) follows specific guidelines that dictate its use as an enzymatic adjuvant. The medicine is primarily administered via subcutaneous (SC) injection or infusion and must not be given intravenously (IV), as the enzyme is rapidly inactivated, rendering its spreading effects unachievable via that route.

The product is used as an event-driven, single-use injection, always administered immediately prior to or concurrent with the substance requiring enhanced dispersion; it is not used as a daily or scheduled medication.

Dosage and Administration

Procedure	Standard Dosing (Adults)	Administration Timing
Subcutaneous Fluid Administration (Hypodermoclysis)	150 USP units	Injected prior to or into the subcutaneous fluid line
Increasing Dispersion of Injected Drugs	50 U to 300 U (typically 150 U)	Added directly to the drug solution or administered first
Subcutaneous Urography	75 U over each scapula	Administered followed by contrast medium injection

Procedural and Population Constraints

Administration protocols require careful adherence to procedural constraints. When used for hypodermoclysis, the total volume and flow rate of the co-administered fluid must be controlled and generally should not exceed limits used for standard intravenous infusion. Furthermore, there are special restrictions for use in premature infants and neonates undergoing hypodermoclysis, where the daily fluid volume must not be more than 25 mL/kg of body weight, and the administration rate must not exceed 2 mL per minute. The medicine is supplied as an injectable solution and must be visually inspected for particulate matter before use.

Research evidence / Overview of Studies for Лидаза

---

Evidence for Enhancing Subcutaneous Fluid Absorption

Research has explored the temporary role of the enzyme in the administration of fluids under the skin, a process sometimes studied in contexts related to hydration. Research examined this use primarily in short-term Randomized Controlled Trials (RCTs) and prospective studies. These trials were observed in populations including children needing hydration and adults in settings requiring supportive hydration. Researchers monitored outcomes related to the rate of fluid infusion, the total volume that can be delivered, and localized outcomes related to physical discomfort at the injection site.

The findings describe patterns observed in the studies where the enzyme was associated with measurements of increased fluid flow and larger administered volumes compared to subcutaneous administration alone. Studies report how symptoms evolved in the observed populations, specifically noting patterns where the enzyme-assisted delivery was observed in comparison to standard intravenous fluid delivery in certain patient groups. However, findings related to patient-reported outcomes describing perceived discomfort were mixed across different trials.

Studies on Dispersion of Co-administered Injected Drugs

The enzyme was evaluated in studies exploring its role in increasing the localized spread and absorption of other medications, such as local anesthetics. Studies explored how the enzyme affects the speed of absorption and the local area of distribution when co-administered. The data show patterns related to a wider distribution and faster onset of the co-administered drug effects in certain situations, such as nerve blocks for ophthalmic surgery. This research contributes to understanding symptom patterns related to the enzyme's role as a spreading factor.

Evidence Gaps and Areas of Research Uncertainty

The research landscape shows several limitations. For many indications, sample sizes were modest, and evidence quality varies across studies, particularly where controlled trials are difficult to execute (e.g., extravasation management). Comparative evidence is lacking for many potential drug combinations. The results apply only to the populations studied, and researchers acknowledge that the extent of the effect may vary widely depending on the patient and the specific context. This means that while studies help show what has been observed so far, research provides context but not individual predictions.

Key Studies & References

1. Therapeutic Promise of Hyaluronidase in Systemic Sclerosis: A Systematic Review (Review of Case Studies/Series for Fibrous Tissue)
2. Clinical Practice Guidelines: Peripheral extravasation injuries: Initial management and washout procedure (Royal Children's Hospital, Melbourne)
3. GUIDELINE FOR MANAGEMENT OF EXTRAVASATION (East Midlands Cancer Alliance)

Common questions about Лидаза (FAQ)

Q: Is Lidaza an antibiotic or a hormonal drug?

A: According to official regulatory documents, Lidaza (Hyaluronidase) is described as an enzyme that belongs to the pharmacological class of glycoside hydrolases. It is a protein-based biologic medicine, and it is not classified as an antibiotic or a hormonal drug.

Q: What are the main uses for Lidaza injections?

A: The primary approved use for the injection is to temporarily enhance the absorption and spread of other specific medicines that are administered subcutaneously (under the skin) or intramuscularly (into the muscle). It is also used to help facilitate the subcutaneous delivery of fluids (hypodermoclysis) and during subcutaneous urography.

Q: For what conditions is Lidaza used in ophthalmology?

A: In official protocols, the drug may be used in ophthalmology to improve the penetration and diffusion of local anesthetics. This application is typically for nerve blocks administered before eye surgery.

Q: Does Lidaza help with scars, and what kind of scars are treated?

A: The officially approved indications for Lidaza are to enhance the penetration of other injections and facilitate fluid absorption. Research has investigated the use of the drug for localized applications in connection with keloid and hypertrophic scars, though official regulatory approval is focused on its role as a spreading factor.

Q: Can Lidaza be used for post-operative adhesions?

A: Official indications focus on enhancing the spread of other injected drugs. In some clinical studies, the medicine was investigated as an auxiliary tool for managing conditions related to adhesions, such as those in the epidural space, after surgical procedures. This is not listed as a primary approved indication.

Q: Is Lidaza really used for pulmonary tuberculosis?

A: The official uses for the drug do not include the therapeutic treatment of pulmonary tuberculosis itself. However, in some research studies, it has been investigated as an ancillary agent for use in relation to complications that may be associated with conditions like tuberculous meningitis and arachnoiditis.

Q: What is Lidaza used for in gynecology?

A: Official prescribing information does not list specific gynecological treatment as an indication. In clinical research, studies have explored the drug's use in contexts related to tissue management during childbirth, specifically concerning the perineum. This application is not an officially approved use.

Q: Is Lidaza used in cosmetology?

A: Official labeling does not mention cosmetic applications. In dermatological practice, the product is sometimes used unofficially (off-label) in connection with complications that may arise from hyaluronic acid-based dermal fillers.

Q: Can Lidaza be used to dissolve fillers?

A: Official product information does not include this application. Due to the drug's mechanism involving the breakdown of hyaluronic acid, it is used unofficially (off-label) to address hyaluronic acid fillers.

Q: How soon can I expect an effect from Lidaza treatment?

A: The official administration protocols describe its use immediately prior to or concurrent with the substance requiring enhanced dispersion. Pharmacokinetic data suggests that the action of the enzyme upon injection is rapid.

Q: How long does the effect of Lidaza last after one injection?

A: Studies indicate that the effect of the enzyme on tissue permeability is temporary and reversible. This change in tissue permeability may last between 24 and 48 hours, after which the tissue returns to its normal state.

Q: What should I do if redness and swelling appear after a Lidaza injection?

A: Redness and swelling at the injection site are officially documented as common local adverse reactions to the medication. The appearance of these local reactions should be discussed with the healthcare professional administering the drug.

Q: Can Lidaza cause fever or chills?

A: Systemic reactions like fever or chills are generally not listed as common side effects in official regulatory documents. Documented systemic reactions typically include general discomfort, nausea, and dizziness.

Q: Can Lidaza treatment be combined with alcohol?

A: Official regulatory sources do not contain specific information regarding any known interaction between the drug Lidaza and alcohol.

Q: Can Lidaza be used if I have a malignant neoplasm?

A: Official labeling restricts the injection of the medicine into areas where a malignant neoplasm (a cancerous tumor) is present. Restrictions also describe avoiding areas that are infected or inflamed.

Q: Why is Lidaza contraindicated in recent hemorrhages?

A: The official instructions advise against injecting the product into sites of recent hemorrhage (bleeding), inflammation, or infection. The restriction against injecting into sites of recent hemorrhage, inflammation, or infection is officially stated to relate to the potential for the drug to enhance the spread of the condition.

Q: Is Lidaza a drug used for disease prevention?

A: No. Official administration guidelines state that the drug is intended for single-use, event-driven application as an adjuvant (a spreading factor). It is not used as a daily or scheduled medication for the prevention of diseases.

Q: How often should Lidaza injections be given as part of a course of treatment?

A: Official protocols primarily describe the single, situational use of the product to facilitate the delivery of another drug. When a course of treatment for non-approved uses is followed, the required frequency is not defined in the core regulatory documents.

Q: What is known about the use of Lidaza for a spinal hernia?

A: Official uses do not include the therapeutic treatment of spinal disc herniation. In some research studies, the product has been investigated as an auxiliary agent during epidural steroid injections in connection with pain management for patients after certain back procedures.

Q: Why can Lidaza cause temporary visual disturbances when used in ophthalmology?

A: Official documentation does not list frequent visual disturbances. However, the safety profile does note that in rare reports related to allergic reactions in the ophthalmological setting, swelling around the eyes (periorbital edema) has been observed.

Q: In what cases is Lidaza used to prepare for skin grafting/plastic surgery?

A: Although not officially indicated for pre-surgical preparation, the product's function to improve the spread of local anesthetics or facilitate the resorption of fluid or blood in tissues suggests potential application in this area. Its use is guided by a healthcare professional.

Q: What is known about the use of Lidaza for scleroderma?

A: The official indications do not cover scleroderma. In some unofficial dermatological research, the product has been studied in contexts related to conditions involving mucin deposition in tissues.

Q: Can Lidaza help with hematomas?

A: Official European product information states that one documented function is to facilitate the localized resorption of excess fluid and blood, including hematomas (collections of blood) in the tissues.

Q: Can Lidaza be used for inhalation?

A: The official protocols for the drug describe its administration exclusively as an injection (subcutaneous or intramuscular) or infusion. Inhalation administration is not specified or approved in the official prescribing information.

Q: Is a doctor's prescription needed to buy Lidaza at the pharmacy?

A: In most regulatory jurisdictions, this medicine is classified as a Prescription Only Medicine (P.O.M.). This means it is generally dispensed by a pharmacy only with a valid prescription from a licensed healthcare provider.

Q: What should I do if I miss a scheduled Lidaza injection?

A: The product is typically administered by a professional under a specific plan. Information regarding a missed administration should be obtained from the prescribing doctor or pharmacist to ensure the correct schedule is followed.

Storage and Handling Requirements

Official regulatory guidelines for Лидаза (Hyaluronidase) focus on preserving the stability of the enzyme preparation.

Storage & Disposal Scope	Official Regulatory Requirement
Labeled storage temperature:	Store the unopened product under refrigerated conditions between 2 C and 8 C (36 F and 46 F).
Prohibited conditions:	The medicine must not be frozen and should be protected from light.
Stability after reconstitution:	The product is designated for single-use only. Any unused portion or remainder must be discarded immediately after preparation.
Child-protection storage:	Keep out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Disposal must adhere to specific regulatory protocols for pharmaceutical waste.

• Dispose of any unused or expired medicine in accordance with local requirements.
• The product should not be disposed of in wastewater or sewage systems.